Gina Mauro currently serves as Vice President of Content at MJH Life Sciences, overseeing OncLive®, Oncology Nursing News®, and Medical World News®. Gina joined the company in 2015 and has held various positions on OncLive and Oncology Nursing News. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: [email protected]
Patients with mantle cell lymphoma (MCL) who have high-risk biology, including blastoid variant, a Ki-67 score of at least 30%, or high p53 expression, had a significantly shorter failure-free and overall survival (OS), according to results of a retrospective trial.
